Update on stents: Recent studies on the TAXUS® stent system in small vessels

Vascular Health and Risk Management

Volumn 3, Issue 4, 2007, Pages 481-490

  Tanimoto, Shuzou ^a   Daemen, Joost ^a   Serruys, Patrick W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Coronary artery disease; Paclitaxel; Restenosis; Stent

Indexed keywords

ANTITHROMBOCYTIC AGENT; COPOLYMER; METAL; PACLITAXEL; RAPAMYCIN;

BREAST CANCER; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY THROMBOSIS; CORONARY STENT; DEATH; DRUG EFFICACY; DRUG ELUTING STENT; DRUG IMPLANTATION; DRUG RELEASE; FEASIBILITY STUDY; HEART INFARCTION; HUMAN; INTERMETHOD COMPARISON; NONHUMAN; OVARY CANCER; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RESTENOSIS; REVASCULARIZATION; REVIEW; THROMBOSIS;

BLOOD VESSELS; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; PACLITAXEL; SIROLIMUS; STENTS;

EID: 35148872240     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Agostoni P, Biondi-Zoccai GG, Gasparini GL, et al. 2005. Is bare-metal stenting superior to balloon angioplasty for small vessel coronary artery disease? Evidence from a meta-analysis of randomized trials. Eur Heart J, 26:881-9.
2. Akiyama T, Moussa I, Reimers B, et al. 1998. Angiographic and clinical outcome following coronary stenting of small vessels: a comparison with coronary stenting of large vessels. J Am Coll Cardiol, 32:1610-8.
3. Aoki J, Colombo A, Dudek D, et al. 2005a. Peristent remodeling and neointimal suppression 2 years after polymer-based, paclitaxel-eluting stent implantation: insights from serial intravascular ultrasound analysis in the TAXUS II study. Circulation, 112:3876-83.
4. Aoki J, Abizaid AC, Serruys PW, et al. 2005b. Evaluation of four-year coronary artery response after sirolimus-eluting stent implantation using serial quantitative intravascular ultrasound and computer-assisted grayscale value analysis for plaque composition in event-free patients. J Am Coll Cardiol, 46:1670-4.
5. Aoki J, Abizaid AC, Ong AT, et al. 2005c. Serial assessment of tissue growth inside and outside the stent after implantation of drug-eluting stent in clinical trials. - Does delayed neointimal growth exist? EuroInterv, 1:253-5.
6. Ardissino D, Cavallini C, Bramucci E, et al. 2004. Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA, 292:2727-34.
7. Axel DI, Kunert W, Goggelmann C, et al. 1997. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation, 96:636-45.
8. Bauters C, Hubert E, Prat A, et al. 1998. Predictors of restenosis after coronary stent implantation. J Am Coll Cardiol, 1291-8.
9. Betriu A, Masotti M, Serra A, et al. 1999. Randomized comparison of coronary stent implantation and balloon angioplasty in the treatment of de novo coronary artery lesions (START): a four-year follow-up. J Am Coll Cardiol, 34:1498-506.
10. Briguori C, Sarais C, Pagnotta P, et al. 2002. In-stent restenosis in small coronary arteries: impact of strut thickness. J Am Coll Cardiol, 40:403-9.
11. Brophy JM, Belisle P, Joseph L. 2003. Evidence for use of coronary stents. A hierarchical bayesian meta-analysis. Ann Intern Med, 138:777-86.
12. Carter AJ, Aggarwal M, Kopia GA, et al. 2004. Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardiovasc Res, 63:617-24.
13. Colombo A, Drzewiecki J, Banning A, et al. 2003. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation, 108:788-94.
14. Dawkins KD, Grube E, Guagliumi G, et al. 2005. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice. Circulation, 112:3306-13.
15. Degertekin M, Serruys PW, Foley DP, et al. 2002. Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation: long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up. Circulation, 106:1610-3.
16. de Lezo J MA, Pan M, Romero M, et al. 2005. Drug-eluting stents for complex lesions: randomized rapamycin versus paclitaxel CORPAL study. J Am Coll Cardiol, 45:75A.
17. Dibra A, Kastrati A, Mehilli J, et al. 2005. Paclitaxel-eluting or sirolimuseluting stents to prevent restenosis in diabetic patients. N Engl J Med, 353:663-70.
18. Farb A, Heller PF, Shroff S, et al. 2001. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation, 104:473-9.
19. Fischman DL, Leon MB, Baim DS, et al. 1994. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med, 331:496-501.
20. Giannakakou P, Robey R, Fojo T, et al. 2001. Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity. Oncogene, 20:3806-13.
21. Goy JJ, Stauffer JC, Siegenthaler M, et al. 2005. A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology: the TAXi trial. J Am Coll Cardiol, 45:308-11.
22. Grebe E, Silber S, Hauptmann KE, et al. 2003. TAXUS I: six- and twelvemonth results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation, 107:38-42.
23. Guagliumi G, Farb A, Musumeci G, et al. 2003. Images in cardiovascular medicine. Sirolimus-eluting stent implanted in human coronary artery for 16 months: pathological findings. Circulation, 107:1340-1.
24. Hofma SH, van der Giessen WJ, van Dalen BM, et al. 2006. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J, 27:166-70.
25. Holmes DR, Jr., Leon MB, Moses JW, et al. 2004. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation, 109:634-40.
26. Hui A, Min WX, Tang J, et al. 1998. Inhibition of activator protein 1 activity by paclitaxel suppresses interleukin-1-induced collagenase and stromelysin expression by bovine chondrocytes. Arthritis Rheum, 41:869-76.
27. Iakovou I, Schmidt T, Bonizzoni E, et al. 2005. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA, 293:2126-30.
28. Joner M, Finn AV, Farb A, et al. 2006. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol, 48:193-202.
29. Karrillon GJ, Morice MC, Benveniste E, et al. 1996. Intracoronary stent implantation without ultrasound guidance and with replacement of conventional anticoagulation by antiplatelet therapy. 30-day clinical outcome of the French Multicenter Registry. Circulation, 94:1519-27.
30. Kastrati A, Schomig A, Dirschinger J, et al. 2000. A randomized trial comparing stenting with balloon angioplasty in small vessels in patients with symptomatic coronary artery disease. ISAR-SMART Study Investigators. Intracoronary Stenting or Angioplasty for Restenosis Reduction in Small Arteries. Circulation, 102:2593-8.
31. Kastrati A, Mehilli J, von Beckerath N, et al. 2005a. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA, 293:165-71.
32. Kastrati A, Dibra A, Eberle S, et al. 2005b. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. JAMA, 294:819-25.
33. Kastrati A, Dibra A, Mehilli J, et al. 2006. Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents. Circulation, 113:2293-300.
34. Kiemeneij F, Serruys PW, Macaya C, et al. 2001. Continued benefit of coronary stenting versus balloon angioplasty: five-year clinical follow-up of Benestent-I trial. J Am Coll Cardiol, 37:1598-603.
35. Koning R, Eltchaninoff H, Commeau P, et al. 2001. Stent placement compared with balloon angioplasty for small coronary arteries: in-hospital and 6-month clinical and angiographic results. Circulation, 104:1604-8.
36. Lau KW, Ding ZP, Sim LL, et al. 2000. Clinical and angiographic outcome after angiography-guided stent placement in small coronary vessels. Am Heart J, 139:830-9.
37. Macaya C, Serruys PW, Ruygrok P, et al. 1996. Continued benefit of coronary stenting versus balloon angioplasty: one-year clinical follow-up of Benestent trial. Benestent Study Group. J Am Coll Cardiol, 27:255-61.
38. Mak KH, Belli G, Ellis SG, et al. 1996. Subacute stent thrombosis: evolving issues and current concepts. J Am Coll Cardiol, 27:494-503.
39. McFadden EP, Stabile E, Regar E, et al. 2004. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet, 364:1519-21.
40. Mehilli J, Dibra A, Kastrati A, et al. 2006. Randomized trial of paclitaxel-and sirolimus-eluting stents in small coronary vessels. Eur Heart J, 27:260-6.
41. Moer R, Myreng Y, Molstad P, et al. 2001. Stenting in small coronary arteries (SISCA) trial. A randomized comparison between balloon angioplasty and the heparin-coated beStent. J Am Coll Cardiol, 38:1598-603.
42. Moreno R, Fernandez C, Hernandez R, et al. 2005. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol, 45:954-9.
43. Morice MC, Colombo A, Meier B, et al. 2006. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA, 295:895-904.
44. Moses JW, Leon MB, Popma JJ, et al. 2003. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med, 349:1315-23.
45. Moussa I, Di Mario C, Reimers B, et al. 1997. Subacute stent thrombosis in the era of intravascular ultrasound-guided coronary stenting without anticoagulation: frequency, predictors and clinical outcome. J Am Coll Cardiol, 29:6-12.
46. Nebeker JR, Virmani R, Bennett CL, et al. 2006. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol, 47:175-81.
47. Ong AT, McFadden EP, Regar E, et al. 2005. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol, 45:2088-92.
48. Park KH, Park SW, Hong MK, et al. 2006. Comparison of the effectiveness of sirolimus- and paclitaxel-eluting stents for small coronary artery lesions. Catheter Cardiovasc Interv, 67:589-94.
49. Park SW, Lee CW, Hong MK, et al. 2000. Randomized comparison of coronary stenting with optimal balloon angioplasty for treatment of lesions in small coronary arteries. Eur Heart J, 21:1785-9.
50. Popma JJ, Leon MB, Moses JW, et al. 2004. Quantitative assessment of angiographic restenosis after sirolimus-eluting stent implantation in native coronary arteries. Circulation, 110:3773-80.
51. Rodriguez-Granillo GA, Valgimigli M, Garcia-Garcia HM, et al. 2005. One-year clinical outcome after coronary stenting of very small vessels using 2.25 mm sirolimus- and paclitaxel-eluting stents: a comparison between the RESEARCH and T-SEARCH registries. J Invasive Cardiol, 17:409-12.
52. Schampaert E, Cohen EA, Schluter M, et al. 2004. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol, 43:1110-15.
53. Schofer J, Schluter M, Gershlick AH, et al. 2003. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet, 362:1093-9.
54. Serruys PW, de Jaegere P, Kiemeneij F, et al. 1994. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med, 331:489-95.
55. Serruys PW, Kay IP, Disco C, et al. 1999. Periprocedural quantitative coronary angiography after Palmaz-Schatz stent implantation predicts the restenosis rate at six months: results of a meta-analysis of the BElgian NEtherlands Stent study (BENESTENT) I, BENESTENT II Pilot, BENESTENT II and MUSIC trials. Multicenter Ultrasound Stent In Coronaries. J Am Coll Cardiol, 34:1067-74.
56. Silber S, Albertsson P, Aviles FF, et al. 2005. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J, 26:804-47.
57. Stone GW, Ellis SG, Cox DA, et al. 2004a. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med, 350:221-31.
58. Stone GW, Ellis SG, Cox DA, et al. 2004b. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation, 109:1942-7.
59. Stone GW, Ellis SG, Cannon L, et al. 2005. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA, 294:1215-23.
60. Tanabe K, Serruys PW, Grube E, et al. 2003. TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation, 107:559-64.
61. Tanimoto S, Daemen J, Tsuchida K, et al. 2006. Two-year clinical outcome after coronary stenting of small vessels using 2.25 mm sirolimus- and paclitaxel-eluting stents: Insight into the RESEARCH and T-SEARCH registries. Catheter Cardiovasc Interv, in press
62. Virmani R, Guagliumi G, Farb A, et al. 2004. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation, 109:701-5.
63. Weisz G, Leon MB, Holmes DR, Jr., et al. 2006. Two-year outcomes after sirolimus-eluting stent implantation: results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial. J Am Coll Cardiol, 47:1350-5.
64. Windecker S, Remondino A, Eberli FR, et al. 2005. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med, 353:653-62.
65. Wong P, Lau KW, Lim YL, et al. 2000. Stent placement for non-STRESS/v lesions: a critical review. Catheter Cardiovasc Interv, 51:223-33.